Cullinan Therapeutics Announces Phase 3 REZILIENT3 PFS Win for Zipalertinib

What Happened

• On August 12, 2026 Cullinan Therapeutics, together with Taiho Oncology and Taiho Pharmaceutical, announced that the global Phase 3 REZILIENT3 trial evaluating zipalertinib plus platinum-based chemotherapy versus chemotherapy alone met its primary endpoint of progression-free survival (PFS) at a planned interim analysis. The trial tested the combination as first-line treatment for adult patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion (ex20ins) mutations. Observed safety in the zipalertinib arm was described as manageable.

Key Details

• Announcement date: August 12, 2026 (press release furnished as Exhibit 99.1 to the Form 8-K).
• Trial result: REZILIENT3 met the primary endpoint (PFS) at a planned interim analysis, with a statistically significant and clinically meaningful improvement in the zipalertinib-containing arm.
• Independent Data Monitoring Committee (IDMC) recommended unblinding the trial; the study will continue to monitor efficacy and safety.
• Next steps: Full trial results will be submitted for presentation at an upcoming international medical conference, and Cullinan and Taiho plan to pursue U.S. regulatory approval for the zipalertinib plus platinum chemotherapy combination pending discussions with the FDA.

Why It Matters

• For investors, a positive Phase 3 interim readout on the primary endpoint is a major clinical milestone that can materially affect a biotech company's development timeline and regulatory strategy. The companies’ plan to seek U.S. approval (subject to FDA discussions) means potential commercial opportunity if regulators and subsequent data support approval. Continued monitoring and the forthcoming full dataset and regulatory interactions will be key near-term catalysts to watch.